Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajith Nair

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
The American Journal of Medicine|July 2, 2021
Patient Characteristics and Outcomes of Type 2 Myocardial Infarction During Heart Failure Hospitalizations in the United StatesSalik Nazir, Abdul Mannan Khan Minhas, Ishan S Kamat, et al.
Artificial Organs|May 7, 2022
Preoperative hyponatremia and survival after left ventricular assist device implantationHarveen K Lamba, Umang M Parikh, Justin Vincent, et al.
American Journal of Human Genetics|November 13, 2012
Defective presynaptic choline transport underlies hereditary motor neuropathyKaty E S Barwick, Jane Wright, Saeed Al-Turki, et al.
JACC. Clinical Electrophysiology|May 12, 2018
Incidence, Predictors, and Significance of Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices: A 15-Year Institutional ExperienceBrian D Greet, Deep Pujara, David Burkland, et al.
JACC. Clinical Electrophysiology|July 18, 2024
Mortality in Recipients of Durable Left Ventricular Assist Devices Undergoing Ventricular Tachycardia AblationPatrick T Lynch, Alexandra Maloof, Anish Badjatiya, et al.
JACC. Heart Failure|February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline CharacteristicsPablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
JACC. Heart Failure|July 22, 2023
Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection FractionRavi B Patel, Vivek Y Reddy, Jan Komtebedde, et al.
JACC. Heart Failure|June 10, 2026
Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF IIShunichi Doi, Sho Kazui, Naoyuki Akashi, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
The American Journal of Medicine|July 2, 2021
Patient Characteristics and Outcomes of Type 2 Myocardial Infarction During Heart Failure Hospitalizations in the United StatesSalik Nazir, Abdul Mannan Khan Minhas, Ishan S Kamat, et al.
Artificial Organs|May 7, 2022
Preoperative hyponatremia and survival after left ventricular assist device implantationHarveen K Lamba, Umang M Parikh, Justin Vincent, et al.
American Journal of Human Genetics|November 13, 2012
Defective presynaptic choline transport underlies hereditary motor neuropathyKaty E S Barwick, Jane Wright, Saeed Al-Turki, et al.
JACC. Clinical Electrophysiology|May 12, 2018
Incidence, Predictors, and Significance of Ventricular Arrhythmias in Patients With Continuous-Flow Left Ventricular Assist Devices: A 15-Year Institutional ExperienceBrian D Greet, Deep Pujara, David Burkland, et al.
JACC. Clinical Electrophysiology|July 18, 2024
Mortality in Recipients of Durable Left Ventricular Assist Devices Undergoing Ventricular Tachycardia AblationPatrick T Lynch, Alexandra Maloof, Anish Badjatiya, et al.
JACC. Heart Failure|February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline CharacteristicsPablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
American Heart Journal|September 5, 2024
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trialsSheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
JACC. Heart Failure|July 22, 2023
Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection FractionRavi B Patel, Vivek Y Reddy, Jan Komtebedde, et al.
JACC. Heart Failure|June 10, 2026
Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF IIShunichi Doi, Sho Kazui, Naoyuki Akashi, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Pageof 5